ACAD Stock: Price, Earnings History and SEC Filings
Acadia Pharmaceuticals Inc. (ACAD) last traded at $20.59, down 0.82% on the latest session and up 2.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.18 against an analyst estimate of $0.06, a beat of 200.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ACAD earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $0.18 | $0.06 | +200.00% |
| Mar 2026 | May 6, 2026 | $0.02 | $0.04 | -50.00% |
| Dec 2025 | Feb 25, 2026 | $0.16 | $0.12 | +33.33% |
| Sep 2025 | Nov 5, 2025 | $0.26 | $0.14 | +85.71% |
ACAD beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How ACAD reacts to earnings
Across its last 8 earnings releases, ACAD moved 4.3% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | +6.08% |
| 2026-05-06 | After close | +5.03% |
| 2026-02-25 | After close | -1.32% |
| 2026-01-13 | Before open | -0.49% |
| 2025-11-05 | After close | -3.05% |
| 2025-08-06 | After close | +2.52% |
| 2025-05-07 | After close | +14.31% |
| 2025-02-26 | After close | +1.79% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ACAD financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.1B | $391M | $105M | 36.5% | $2.30 |
| 2024 | $958M | $226M | $157M | 23.6% | $1.36 |
| 2023 | $726M | -$61M | $17M | -8.4% | $-0.37 |
| 2022 | $517M | -$216M | -$114M | -41.8% | $-1.34 |
| 2021 | $484M | -$168M | -$127M | -34.7% | $-1.05 |
| 2020 | $442M | -$282M | -$144M | -63.7% | $-1.79 |
| 2019 | $339M | -$235M | -$152M | -69.4% | – |
| 2018 | $224M | -$245M | -$170M | -109.6% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ACAD
- 8-K · Oct 23, 2026Officer or director change
- 8-K · Sep 24, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 11, 2026Other events, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · May 29, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 8-K · May 1, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
Insider filing activity
ACAD insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ACAD news
- Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026Oct 28, 2026 · finance.yahoo.com
- Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026Oct 21, 2026 · finance.yahoo.com
- Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?Oct 21, 2026 · finance.yahoo.com
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. (ACAD) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.